Tag: Biologics
-
Biocon Biologics and Biocon to Merge: Key Developments within the Biopharmaceutical Sector
Biocon to accumulate stability stake in Biocon Biologics at EV of USD 5.5 billion Biocon introduced a strategic company motion to totally combine Biocon Biologics (BBL) as an entirely owned subsidiary into Biocon, topic to relevant approvals. The Technique Committee, constituted in Might 2025, undertook a complete analysis of a number of strategic choices for…
-
Biocon to Consolidate Biologics Division in $5.5 Billion Merger
Biocon Ltd will combine Biocon Biologics Ltd as an entirely owned subsidiary in a deal valuing the unit at $5.5 billion, the corporate mentioned on Saturday. Biocon will purchase the remaining stake in Biocon Biologics from Serum Institute Life Sciences, Tata Capital Progress Fund II and Activ Pine LLP through a share swap of 70.28…